Results 21 to 30 of about 12,232 (185)
Revue medicale suisse, 2017 Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta +7 more
openaire +3 more sources
The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
Journal of Education, Health and Sport, 2023 Introduction and aim. Cardiovascular diseases are the main cause of mortality in the world. One of the alterable risk factors of ischaemic heart disease is dyslipidemia.
Natalia Ilnicka +4 more
doaj +1 more source
PCSK9 Inhibition: From Current Advances to Evolving Future
Cells, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein ...
Chunping Liu +14 more
doaj +1 more source
PCSK9 inhibitors and diabetes mellitus [PDF]
Vnitřní lékařství, 2018 Proproteinconvertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor (LDLR) expression. Anti-PCSK9 monoclonal antibody (MAb) therapy reduces LDL-cholesterol (LDL-C) by ~60 % and reduces also the risk of major adverse cardiovascular events.
Branislav, Vohnout +2 more
openaire +2 more sources
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model [PDF]
PeerJBackground The incidence of diabetes-associated cognitive dysfunction (DACD) is increasing; however, few clinical intervention measures are available for the prevention and treatment of this disease.
Yang Yang +4 more
doaj +2 more sources
PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease [PDF]
Farmacja Polska, 2020 Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9).
Natalia Pauli, Monika Rac
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent LDL-C lowering agents. However, few head-to-head studies evaluated the efficacy on the lowering in other atherogenic apolipoproteins and safety of PCSK9 ...
Yi-Ting Huang +9 more
doaj +1 more source
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Proceedings of Singapore Healthcare, 2022 Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains unclear whether the results can be translated to Asian populations. This study
Bee Ling Kelly Chng +6 more
doaj +1 more source
Biomedicine & Pharmacotherapy, 2022 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged as a therapeutic option for patients with hypercholesterolemia who do not attain low-density lipoprotein cholesterol (LDL-C) goals and/or are intolerant to other lipid-lowering drugs.
Juan, Vicente-Valor +9 more
openaire +2 more sources
Frontiers in PharmacologyBackgroundCurrently, there are various lipid-lowering therapies in clinical practice, and the emergence of PCSK9 inhibitors has undoubtedly added a valuable tool to lipid-lowering strategies.
Qiang Niu, Qilei Wang, Feng Chen, Bo Li
doaj +1 more source